OmniAb Investor Presentation Deck slide image

OmniAb Investor Presentation Deck

Antibodies and Industry Demand HIGHER CLINICAL SUCCESS RATES FOR ANTIBODY MEDICINES DRIVE OUR INDUSTRY'S NEED FOR DISCOVERY TECHNOLOGY Increasing Antibody Market ā— $279B in antibody sales by 2025 (up from ~$238B in 2022) 51 blockbuster antibodies in 2022 5 best-selling antibodies had ~$75B of sales in 2022 Higher Success Rates Type of Drug Small Molecules Antibodies Clinical Success Rates (1) 7.5% 12.1% Historical success rates for antibodies are significantly higher than small molecules Acceleration of Regulatory Approvals (FDA and EMA) 70 60 50 40 30 20 10 0 Substantial growth in number of new antibody therapeutics Pre-2000 2001-2010 2011-2020 Sources: Clarivate Analytics Cortellis database. Tables of approved mAbs and antibodies in review available at: https://www.antibodysociety.org/resources/approved-antibodies/ (1) Defined as composite success rate of clinical development from Phase I trials to Approval, data from 2011-2020. Source: BIO | QLS Advisors | Informa Feb 2021 Report. LO 5 OmniAb
View entire presentation